Pharmacoeconomic analysis of erlotinib as second-line treatment of advanced non-small cell lung cancer in Taiwan

被引：0
|
作者：
Hsia, T. [1 ]
Chang, G. [2 ]
Chen, Y. [3 ]
Lin, M. [4 ]
Su, W. [5 ]
Tsai, C. [3 ,6 ]
Tsai, C. [3 ,6 ]
Yang, L. [6 ]
机构：
[1] China Med Univ Hosp, Dept Pulm Med, Taichung, Taiwan
[2] Taichung Vet Gen Hosp, Dept Pulm Med, Taichung, Taiwan
[3] Vet Gen Hosp, Chest Dept, Taipei, Taiwan
[4] Chang Guang Mem Hosp, Dept Pulm & Crit Care Med, Kaohsiung, Taiwan
[5] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[6] Roche Prod Ltd, Dept Pharma, Taipei, Taiwan
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71386-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6558
引用
收藏
页码：375 / 375
页数：1
相关论文
共 50 条
  • [31] Second-line chemotherapy for non-small cell lung cancer
    De Marinis, F.
    De Santis, S.
    De Petris, L.
    ANNALS OF ONCOLOGY, 2006, 17 : V68 - V71
  • [32] Second-line chemotherapy for non-small cell lung cancer
    Ruckdeschel, JC
    CHEST, 2006, 129 (04) : 840 - 842
  • [33] Non-small cell lung cancer: second-line and beyond
    Stahel, R. A.
    ANNALS OF ONCOLOGY, 2006, 17 : X97 - X100
  • [34] From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?
    Ettore D’Argento
    Sabrina Rossi
    Giovanni Schinzari
    Antonia Strippoli
    Michele Basso
    Alessandra Cassano
    Carlo Barone
    Current Treatment Options in Oncology, 2016, 17
  • [35] From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?
    D'Argento, Ettore
    Rossi, Sabrina
    Schinzari, Giovanni
    Strippoli, Antonia
    Basso, Michele
    Cassano, Alessandra
    Barone, Carlo
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (12)
  • [36] Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer
    Reckamp, Karen L.
    CANCER LETTERS, 2012, 321 (02) : 101 - 109
  • [37] Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer
    Cucevic, B
    Samarzija, M
    Baricevic, D
    Jakopovic, M
    Redzepi, G
    Samija, M
    COLLEGIUM ANTROPOLOGICUM, 2005, 29 (02) : 583 - 588
  • [38] The Role of Pemetrexed in Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer
    Tucker, Steven
    CURRENT DRUG TARGETS, 2010, 11 (01) : 58 - 60
  • [39] Erlotinib in non-small cell lung cancer (NSCLC) in Germany - A cost-saving second-line treatment option?
    Gabriel, A.
    Pirk, O.
    Kotowa, W.
    VALUE IN HEALTH, 2006, 9 (06) : A278 - A278
  • [40] Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer A Real-World Cost-Effectiveness Analysis
    Cromwell, Ian
    van der Hoek, Kimberly
    Melosky, Barbara
    Peacock, Stuart
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (12) : 2097 - 2103
12345